0
Your cart
Anti-Alpha-Synuclein, ASyM-Biotinylated, Mouse, Monoclonal

Anti-Alpha-Synuclein, ASyM-Biotinylated, Mouse, Monoclonal

$649
Read more...

    Description

    Article no.: AS13 2719B

    Product Information

    Immunogen

    Synthetic peptide derived from human Alpha-Synuclein N-terminal, amino acids 1-15.

    Host

    Mouse

    Clonality

    Monoclonal

    Subclass/isotype

    IgG2a

    Purity

    Affinity purified

    Format

    Lyophilized

    Quantity

    50 µg

    Reconstitution

    For reconstitution add 50 µl of sterile water.

    Storage



    For short time storage add sodium azide and store at +4°C.
    For long time storage store lyophilized/reconstituted at -20°C; once reconstituted make aliquots to avoid repeated freeze-thaw cycles. Please, remember to spin tubes briefly prior to opening them to avoid any losses that might occur from lyophilized material adhering to the cap or sides of the tubes.

    Tested applications

    ELISA (ELISA)

    Recommended Dilution

    2-4 ug/ml (ELISA capture)

    Expected | apparent MW

    14 kDa


    Reactivity

    Confirmed Reactivity

    Human

    Not reactive in

    No confirmed exceptions from predicted reactivity are currently known.


    Additional Information

    Additional information

    This antibody is biotinylated.
    Cross reactivity of this antibody to synuclein beta was not determined.


    Related Products

    Related products

    Available antibodies targeting Alpha-Synuclein


    Background

    Background






    Alpha-synuclein is normally an unstructured soluble protein that can aggregate to form insoluble fibrils in pathological conditions characterized by Lewy bodies, such as Parkinson's disease, dementia with Lewy-bodies, and multiple system atrophy. In analogy to many other amyloid associated disorders, alpha-synuclein may also form oligomeric assemblies. These small and soluble forms have been suggested to exert a stronger tissue damaging effect as compared to the monomeric and fibrillar counterpart. Using a recently developed technique a monoclonal oligomer-specific antibody has been designed. 



    Product Citations

    Product citations

    To be added when available.